{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:49Z","timestamp":1783930369821,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00228-026-04094-8","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:40:14Z","timestamp":1781509214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6601-0833","authenticated-orcid":false,"given":"Syeda Masooma","family":"Jafri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3765-9093","authenticated-orcid":false,"given":"Muhammad Shahzou","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1949-7600","authenticated-orcid":false,"given":"Javeria","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9025-2140","authenticated-orcid":false,"given":"Zainab Ali","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7911-0823","authenticated-orcid":false,"given":"Minhal","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7022-3864","authenticated-orcid":false,"given":"Abia Khalid","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7941-1484","authenticated-orcid":false,"given":"Rana Taha","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"4094_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/IJC.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133\u20131145. https:\/\/doi.org\/10.1002\/IJC.27711","journal-title":"Int J Cancer"},{"key":"4094_CR2","doi-asserted-by":"publisher","DOI":"10.1259\/BJR.20211033","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol. https:\/\/doi.org\/10.1259\/BJR.20211033","journal-title":"Br J Radiol"},{"key":"4094_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010","journal-title":"Breast"},{"key":"4094_CR4","doi-asserted-by":"publisher","DOI":"10.3747\/CO.26.5003","volume":"26","author":"M Powis","year":"2019","unstructured":"Powis M, Groome P, Biswanger N, Kendell C, Decker KM, Grunfeld E et al (2019) Cross-Canada differences in early-stage breast cancer treatment and acute-care use. Curr Oncol 26:e624\u201339. https:\/\/doi.org\/10.3747\/CO.26.5003","journal-title":"Curr Oncol"},{"key":"4094_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100331","author":"E Gray","year":"2021","unstructured":"Gray E, Figueroa JD, Oikonomidou O, MacPherson I, Urquhart G, Cameron DA et al (2021) Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100331","journal-title":"ESMO Open"},{"key":"4094_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.breast.2016.07.004","volume":"29","author":"R Ferreira","year":"2016","unstructured":"Ferreira R, Palha A, Correia A, Filipe L, Rodrigues P, Costa V (2016) Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study. Breast 29:68\u201373. https:\/\/doi.org\/10.1016\/j.breast.2016.07.004","journal-title":"Breast"},{"key":"4094_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/S12282-019-01001-1","volume":"27","author":"Y Naito","year":"2020","unstructured":"Naito Y, Kai Y, Ishikawa T, Fujita T, Uehara K, Doihara H et al (2020) Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study. Breast Cancer 27:122\u20138. https:\/\/doi.org\/10.1007\/S12282-019-01001-1","journal-title":"Breast Cancer"},{"key":"4094_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4103\/apjon.apjon-2120","volume":"8","author":"X Huang","year":"2021","unstructured":"Huang X, Li X, Li J, Luo L, Chen H, Tan Y et al (2021) Chemotherapy-induced nausea and vomiting in breast cancer patients: a multicenter prospective observational study. Asia-Pac J Oncol Nurs 8:433\u20137. https:\/\/doi.org\/10.4103\/apjon.apjon-2120","journal-title":"Asia-Pac J Oncol Nurs"},{"key":"4094_CR9","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1007\/S00520-016-3080-Y","volume":"24","author":"L Kottschade","year":"2016","unstructured":"Kottschade L, Novotny P, Lyss A, Mazurczak M, Loprinzi C, Barton D (2016) Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer 24:2661\u20132667. https:\/\/doi.org\/10.1007\/S00520-016-3080-Y","journal-title":"Support Care Cancer"},{"key":"4094_CR10","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u201398. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614","journal-title":"J Clin Oncol"},{"key":"4094_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000621","author":"JG Zhou","year":"2020","unstructured":"Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H et al (2020) Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2019-000621","journal-title":"ESMO Open"},{"key":"4094_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00216","author":"AAM Osman","year":"2018","unstructured":"Osman AAM, Elhassan MMA, AbdElrahim BHA, Ahmed FHA, Yousif JBH, Ahmed MAM et al (2018) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a comparative study from Sudan. J Glob Oncol. https:\/\/doi.org\/10.1200\/JGO.17.00216","journal-title":"J Glob Oncol"},{"key":"4094_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13651500510014783","volume":"9","author":"MAC Mudge","year":"2005","unstructured":"Mudge MAC, Davey PJ, Coleman KA, Montgomery W, Croker VS, Mullen K et al (2005) A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials. Int J Psychiatry Clin Pract 9:3\u201315. https:\/\/doi.org\/10.1080\/13651500510014783","journal-title":"Int J Psychiatry Clin Pract"},{"key":"4094_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1177\/0269881109106900","volume":"24","author":"A Cipriani","year":"2010","unstructured":"Cipriani A, Rendell J, Geddes JR (2010) Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis. J Psychopharmacol 24:1729\u20131738. https:\/\/doi.org\/10.1177\/0269881109106900","journal-title":"J Psychopharmacol"},{"key":"4094_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/PH16040603","author":"R Mlambo","year":"2023","unstructured":"Mlambo R, Liu J, Wang Q, Tan S, Chen C (2023) Receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders. Pharmaceuticals Basel. https:\/\/doi.org\/10.3390\/PH16040603","journal-title":"Pharmaceuticals Basel"},{"key":"4094_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/PGPM.S391401","volume":"16","author":"P Kolli","year":"2023","unstructured":"Kolli P, Kelley G, Rosales M, Faden J, Serdenes R (2023) Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. Pharmgenomics Pers Med 16:1097\u20131108. https:\/\/doi.org\/10.2147\/PGPM.S391401","journal-title":"Pharmgenomics Pers Med"},{"key":"4094_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.705866\/BIBTEX","volume":"11","author":"DY Wang","year":"2021","unstructured":"Wang DY, Chen Y, Zhang Y, Shen YQ (2021) The balance between the effectiveness and safety for chemotherapy-induced nausea and vomiting of different doses of Olanzapine (10 mg versus 5 mg): a systematic review and meta-analysis. Front Oncol 11:705866. https:\/\/doi.org\/10.3389\/FONC.2021.705866\/BIBTEX","journal-title":"Front Oncol"},{"key":"4094_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/PHAR.1703","volume":"36","author":"DL Deremer","year":"2016","unstructured":"Deremer DL, Clemmons AB, Orr J, Clark SM, Gandhi AS (2016) Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting. Pharmacotherapy 36:218\u2013229. https:\/\/doi.org\/10.1002\/PHAR.1703","journal-title":"Pharmacotherapy"},{"key":"4094_CR19","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u201397. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"4094_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/S00280-019-03868-5\/TABLES\/3","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y et al (2019) Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 84:147\u2013153. https:\/\/doi.org\/10.1007\/S00280-019-03868-5\/TABLES\/3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4094_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BCTT.S12955","volume":"3","author":"VTC Chan","year":"2011","unstructured":"Chan VTC, Yeo W (2011) Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. Breast Cancer: Targets Therapy 3:151\u2013160. https:\/\/doi.org\/10.2147\/BCTT.S12955","journal-title":"Breast Cancer: Targets Therapy"},{"key":"4094_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","volume":"112","author":"J Yoodee","year":"2017","unstructured":"Yoodee J, Permsuwan U, Nimworapan M (2017) Efficacy and safety of Olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol 112:113\u2013125. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.017","journal-title":"Crit Rev Oncol Hematol"},{"key":"4094_CR23","doi-asserted-by":"publisher","DOI":"10.18549\/PHARMPRACT.2017.01.877","author":"L Chelkeba","year":"2017","unstructured":"Chelkeba L, Gidey K, Mamo A, Yohannes B, Matso T, Melaku T (2017) Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Granada). https:\/\/doi.org\/10.18549\/PHARMPRACT.2017.01.877","journal-title":"Pharm Pract (Granada)"},{"key":"4094_CR24","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/S00520-020-05935-7\/FIGURES\/4","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439\u20133459. https:\/\/doi.org\/10.1007\/S00520-020-05935-7\/FIGURES\/4","journal-title":"Support Care Cancer"},{"key":"4094_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13643-016-0384-4\/FIGURES\/6","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:1\u201310. https:\/\/doi.org\/10.1186\/S13643-016-0384-4\/FIGURES\/6","journal-title":"Syst Rev"},{"key":"4094_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/SIM.1186","journal-title":"Stat Med"},{"key":"4094_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"},{"key":"4094_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/J.JCLINEPI.2020.09.018","volume":"129","author":"JL Brozek","year":"2021","unstructured":"Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA et al (2021) GRADE guidelines 30: the GRADE approach to assessing the certainty of modeled evidence\u2014an overview in the context of health decision-making. J Clin Epidemiol 129:138\u201350. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2020.09.018","journal-title":"J Clin Epidemiol"},{"key":"4094_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/J.BREAST.2022.06.007\/ASSET\/0939A729-214D-4539-B5C7-A4821BAB1CA7\/MAIN.ASSETS\/GR2.JPG","volume":"65","author":"AT Vuger","year":"2022","unstructured":"Vuger AT, Tiscoski K, Apolinario T, Cardoso F (2022) Anthracyclines in the treatment of early breast cancer friend or foe? Breast 65:67\u201376. https:\/\/doi.org\/10.1016\/J.BREAST.2022.06.007\/ASSET\/0939A729-214D-4539-B5C7-A4821BAB1CA7\/MAIN.ASSETS\/GR2.JPG","journal-title":"Breast"},{"key":"4094_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/J.JRADNU.2023.04.002","volume":"42","author":"S Gautam","year":"2023","unstructured":"Gautam S, Sharma KK, Amanat M (2023) Management of chemotherapy induced nausea vomiting (CINV) in breast cancer patients: an imperative factor in patient compliance. J Radiol Nurs 42:315\u201320. https:\/\/doi.org\/10.1016\/J.JRADNU.2023.04.002","journal-title":"J Radiol Nurs"},{"key":"4094_CR31","doi-asserted-by":"publisher","first-page":"877","DOI":"10.21873\/ANTICANRES.12297","volume":"38","author":"M Nawa-Nishigaki","year":"2018","unstructured":"Nawa-Nishigaki M, Kobayashi R, Suzuki A, Hirose C, Matsuoka R, Mori R et al (2018) Control of nausea and vomiting in patients receiving anthracycline\/cyclophosphamide chemotherapy for breast cancer. Anticancer Res 38:877\u2013884. https:\/\/doi.org\/10.21873\/ANTICANRES.12297","journal-title":"Anticancer Res"},{"key":"4094_CR32","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/S00520-016-3075-8\/TABLES\/5","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N et al (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392. https:\/\/doi.org\/10.1007\/S00520-016-3075-8\/TABLES\/5","journal-title":"Support Care Cancer"},{"key":"4094_CR33","doi-asserted-by":"publisher","unstructured":"Hiremath SB, Devendrappa SL Pharmacology and Clinical Pharmacy Research The Efficacy and Safety of Adding Olanzapine to Triple Drugs Regimen to Prevent Chemotherapy-induced Nausea and Vomiting: A systematic Review and Meta-analysis of RCTs Pharmacology and Clinical Pharmacy Research n.d. https:\/\/doi.org\/10.15416\/pcpr.v7i2.37936","DOI":"10.15416\/pcpr.v7i2.37936"},{"key":"4094_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","volume":"54","author":"M Clemons","year":"2020","unstructured":"Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A et al (2020) A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. The Breast 54:278\u201385. https:\/\/doi.org\/10.1016\/j.breast.2020.11.002","journal-title":"The Breast"},{"key":"4094_CR35","doi-asserted-by":"publisher","first-page":"e12531","DOI":"10.1200\/JCO.2024.42.16_SUPPL.E12531","volume":"42","author":"T Tvsvgk","year":"2024","unstructured":"Tvsvgk T, Thinley D (2024) An open-label randomized trial comparing addition of olanzapine 5 mg versus olanzapine 10 mg as anti-emetic to standard anti-emetic regime for doxorubicin or epirubicin and cyclophosphamide in breast cancer. J Clin Oncol 42:e12531\u2013e12531. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.E12531","journal-title":"J Clin Oncol"},{"key":"4094_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/S00520-021-06606-X","volume":"30","author":"R Chow","year":"2022","unstructured":"Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH (2022) Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer 30:1015\u20138. https:\/\/doi.org\/10.1007\/S00520-021-06606-X","journal-title":"Support Care Cancer"},{"key":"4094_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.JCP.0000085406.08426.A8","volume":"23","author":"RW Baker","year":"2003","unstructured":"Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL (2003) Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 23:342\u2013348. https:\/\/doi.org\/10.1097\/01.JCP.0000085406.08426.A8","journal-title":"J Clin Psychopharmacol"},{"key":"4094_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep04813","author":"XF Wang","year":"2014","unstructured":"Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep. https:\/\/doi.org\/10.1038\/srep04813","journal-title":"Sci Rep"},{"key":"4094_CR39","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"4094_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08221-4","volume":"32","author":"J Herrstedt","year":"2023","unstructured":"Herrstedt J, Celio L, Hesketh P et al (2023) <article-title update=\u201cadded\u201d>2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Support Care Cancer 32:47. https:\/\/doi.org\/10.1007\/s00520-023-08221-4","journal-title":"Support Care Cancer"},{"key":"4094_CR41","unstructured":"https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415"},{"issue":"4","key":"4094_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.21037\/apm.2019.08.04","volume":"8","author":"P Tienchaiananda","year":"2019","unstructured":"Tienchaiananda P, Nipondhkit W, Maneenil K et al (2019) A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med 8(4):372\u2013380. https:\/\/doi.org\/10.21037\/apm.2019.08.04","journal-title":"Ann Palliat Med"},{"key":"4094_CR43","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L et al (2020) A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast 50:30\u201338. https:\/\/doi.org\/10.1016\/j.breast.2020.01.005","journal-title":"Breast"},{"issue":"7","key":"4094_CR44","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S1470-2045(25)00233-5","volume":"26","author":"M Saito","year":"2025","unstructured":"Saito M, Iihara H, Shimokawa M et al (2025) Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 26(7):960\u2013970. https:\/\/doi.org\/10.1016\/S1470-2045(25)00233-5","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04094-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04094-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04094-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:57:25Z","timestamp":1783929445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04094-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4094"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04094-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This is not applicable, as our study is a review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number & ethics"}},{"value":"During the preparation of this work, the authors used Grammarly to paraphrase and format the text to improve clarity. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the manuscript preparation process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}